期刊
GROWTH FACTORS
卷 37, 期 3-4, 页码 105-119出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/08977194.2019.1652399
关键词
Mesenchymal stem cells (MSCs); hepatocyte growth factor (HGF); liver cirrhosis; stem cell therapy
资金
- Business for Cooperative R&D between Industry, Academy, and Research Institutes - Korean Small and Medium Business Administration in 2016 [C0443066]
- Gachon University Gil Medical Center [2016-14]
- Korea Technology & Information Promotion Agency for SMEs (TIPA) [C0443066] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Nowadays, transplantation of human mesenchymal stem cells (MSCs) has emerged as a potential cellular therapy for liver cirrhosis. Hepatocyte growth factor (HGF) plays an important role in the regeneration of the liver. The objective of the study was to investigate the therapeutic effect of HGF-transfected human umbilical cord blood-derived MSCs on dimethylnitrosamine (DMN)-induced liver fibrosis in rats. HGF-transfected MSCs were transplanted into rats with DMN-induced liver fibrosis. H2O2-induced cytotoxicity, apoptosis and intracellular reactive oxygen species were reduced in HGF-transfected MSCs in HGF-transfected MSCs. Pro-apoptotic proteins, such as cleaved poly (ADP-ribose) polymerase and cleaved caspase-3, were decreased in HGF-transfected MSCs. Biochemical analysis showed that the levels of aspartate aminotransferase and alanine aminotransferase were decreased after transplantation of HGF-transfected MSCs in rat fibrosis. Trichrome staining showed that HGF-transfected MSCs reduced liver damage. Taken together, our study indicated that HGF-transfected MSCs have therapeutic effects on DMN-induced liver fibrosis in rats.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据